California Roundup Lawsuit After the Supreme Court Ruling: What the FIFRA Preemption Decision Means for Your Non-Hodgkin Lymphoma Case
You just heard the news. The Supreme Court ruled against Roundup cancer plaintiffs, and the headline says it is a “major blow” to the lawsuits. If you have non-Hodgkin lymphoma and you used Roundup — on your yard in Pasadena, at a worksite in the San Gabriel Valley, during sediment removal at Devil’s Gate Dam, or anywhere across California — your first thought was probably: Is my case over?
The honest answer is: your case is harder, but it is not dead. The ruling closes one door. It does not close the building. What it does is make the specific legal theory your attorney chooses more important than it has ever been — and it makes the evidence of your individual exposure history the foundation everything else is built on.
We are Attorney911 — The Manginello Law Firm. We handle toxic tort cases and catastrophic injury claims, and we take California cases. This page is not a press release about the ruling. It is the analysis a senior trial attorney gives a cancer patient who just learned the legal ground shifted under their case — what the ruling actually held, what it did not reach, which theories survive, what your case is worth now, and what you need to do in the weeks ahead to protect what you still have.
The Ruling in Plain Language: What the Supreme Court Actually Did
The Court held, 7-2, that the Federal Insecticide, Fungicide, and Rodenticate Act — the federal law that gives the EPA authority to approve pesticide labels — preempts state-law failure-to-warn claims that seek to require cancer warnings on Roundup labels the EPA has already approved.
In plain English: Monsanto’s parent company, Bayer, argued that because the EPA reviewed Roundup’s label and concluded glyphosate is “not likely” to cause cancer when used as directed, state courts and state juries cannot impose a different, stricter warning requirement. The Supreme Court agreed. If a plaintiff’s case is built entirely on the theory that “the label should have had a cancer warning and did not,” that specific claim is now preempted — blocked — by federal law.
“FIFRA’s federal labeling scheme preempts state-law failure-to-warn claims that would require cancer warnings beyond those the EPA has approved, because allowing state juries to impose additional warning requirements would directly conflict with the EPA’s regulatory determinations.”
What the ruling did not do is equally important, and it is the part the headlines do not tell you.
What the Ruling Does NOT Eliminate: The Theories That Survive
The Supreme Court addressed one specific type of claim: failure-to-warn claims that seek to change or add to the EPA-approved label. The ruling is rooted in the idea that a state jury cannot impose a labeling requirement that directly conflicts with the federal agency’s determination. That is a narrow holding, and its narrowness is where the surviving claims live.
Here is what the ruling did not touch — legal theories that are not premised on what the label says and therefore do not seek to impose a different labeling requirement:
Design defect. California operates under a strict product liability regime that allows plaintiffs to pursue design defect claims — the theory that the product itself was inherently dangerous in its design, regardless of what the label said. A design defect claim does not ask the jury to add a warning to the label. It asks whether the product was unreasonably dangerous in the way it was formulated. That is a fundamentally different question from “did the label warn adequately,” and it falls outside the preemption the Supreme Court addressed. California courts have long recognized design defect as an independent prong of strict product liability, and the ruling does not erase it.
Negligence in testing and research. A claim that the manufacturer failed to conduct adequate safety testing, or negligently evaluated its own carcinogenicity data, is not a labeling claim. It is a claim about the company’s conduct in the laboratory and in its internal safety reviews — conduct that exists independently of what the label ultimately said. If a company knew its own studies raised cancer concerns and did not investigate further, that is a breach of a duty of care that does not depend on the label’s contents.
Negligent misrepresentation and concealment. If the manufacturer misrepresented safety data to regulators, to the scientific community, or to the public through channels other than the label itself — ghostwritten scientific papers, suppressed internal studies, public statements that minimized cancer risk — a claim based on those out-of-label communications is not a failure-to-warn claim about the label. It is a claim about deceptive conduct that exists separate from the labeling process. Internal Monsanto corporate documents regarding glyphosate safety research and internal knowledge of carcinogenicity risk have already been produced in prior discovery in settled cases. Documents that show corporate knowledge independent of the labeling process may survive a preemption challenge.
Breach of implied warranty. The theory that Roundup was not fit for its ordinary intended use because of its carcinogenic risk operates on a different legal theory than failure-to-warn. Whether it faces its own preemption challenges is a question courts will now litigate, but it is not the claim the Supreme Court just killed.
The critical distinction: any theory that seeks to impose a requirement on the content of the EPA-approved label is preempted. Any theory that challenges the company’s conduct independent of the label’s content is not directly addressed by the ruling and may survive. That is the line your attorney must walk.
The Federal-State Conflict: California’s Proposition 65 vs. the EPA
The Supreme Court’s ruling resolves — in favor of federal preemption — a tension that has been building for years between two regulatory bodies that reached opposite conclusions about the same chemical.
“California’s Proposition 65 lists glyphosate as a chemical known to the State of California to cause cancer, creating a direct conflict with the EPA’s position that glyphosate is not likely carcinogenic when used as directed.”
Here is the background that matters to your case. In 2015, the International Agency for Research on Cancer — the World Health Organization’s cancer arm — classified glyphosate as “probably carcinogenic to humans” (Group 2A). California’s Office of Environmental Health Hazard Assessment then added glyphosate to the Proposition 65 list of chemicals known to the state to cause cancer, based on the IARC determination. The EPA, meanwhile, has repeatedly maintained that glyphosate is “not likely” to be carcinogenic when used according to label directions.
This is not a minor disagreement between bureaucrats. It is a fundamental scientific dispute between two institutions that reach their conclusions through different processes — the IARC evaluates hazard (can it cause cancer under any circumstances), while the EPA evaluates risk (is it likely to cause cancer under real-world use conditions). California sided with the IARC’s hazard assessment. The federal government sided with the EPA’s risk assessment. The Supreme Court’s ruling says that when those two positions conflict, the federal label controls — at least for purposes of failure-to-warn claims.
But the scientific disagreement itself remains. The IARC classification is unchanged. California’s Proposition 65 listing is unchanged. The body of epidemiological and toxicological literature connecting glyphosate exposure to non-Hodgkin lymphoma is unchanged. What changed is one legal theory’s ability to rely on the gap between the California listing and the EPA label. The science that supports design defect, negligence, and concealment theories is the same science that supported the failure-to-warn claims — it just has to be deployed through different legal channels.
The Defendant: Bayer, Monsanto, and the Corporate Structure
The company on the other side of these cases is Bayer AG, the German pharmaceutical and life sciences giant that acquired Monsanto in 2018 for $63 billion. Monsanto Company — the original developer and marketer of Roundup — is now a wholly-owned subsidiary of Bayer. The caption defendant in the litigation is still “Monsanto,” but the money, the board, and the strategic decisions are in Leverkusen, Germany.
The corporate structure matters for several reasons. First, Monsanto’s historical knowledge — the internal safety studies, the corporate communications about glyphosate and cancer, the decisions about what to tell the EPA and what to keep private — all predate the Bayer acquisition. The institutional knowledge that supports negligence and concealment theories lives in Monsanto’s history, but the financial responsibility and the litigation strategy are Bayer’s. Second, Bayer has already paid more than $10 billion to resolve tens of thousands of Roundup claims, and tens of thousands of additional cases remained pending when the Supreme Court agreed to hear the case. Bayer’s litigation strategy — including the decision to push the preemption argument to the Supreme Court — is driven by the scale of its remaining exposure. Third, the corporate structure creates a potential discovery advantage: documents produced in prior settled cases may be available, subject to protective orders and confidentiality agreements, and the pattern of corporate conduct those documents reveal can support non-preempted theories.
The article also references a generic version of glyphosate applied at Caltech facilities. Generic glyphosate manufacturers face the same FIFRA preemption analysis for failure-to-warn claims — if their labels were also EPA-approved, the same preemption logic would likely apply. But design defect and negligence theories can be pursued against generic manufacturers as well, and the specific exposure history at a given location may point to a different defendant than the brand-name product.
Non-Hodgkin Lymphoma: The Disease, the Diagnosis, and the Proof
Non-Hodgkin lymphoma is a cancer of the lymphatic system — the network of vessels, nodes, and organs that carries immune cells throughout the body. It originates in lymphocytes, a type of white blood cell, and can develop in lymph nodes, spleen, bone marrow, or other lymphoid tissue. There are more than 70 subtypes of NHL, with diffuse large B-cell lymphoma being the most common.
The treatment is aggressive. Depending on the subtype and stage, it can include combination chemotherapy (the R-CHOP regimen is standard for many forms), targeted immunotherapy (rituximab), radiation therapy, and — for relapsed or refractory cases — autologous or allogeneic stem cell transplantation. Medical costs range from hundreds of thousands of dollars for standard treatment to well over a million dollars for patients who require transplant and ongoing management. The treatment itself is brutal: the fatigue, the nausea, the immunosuppression, the hair loss, the psychological weight of a cancer diagnosis and months of chemotherapy.
The diagnostics are specific and objective. NHL is diagnosed through lymph node biopsy (excisional or core needle), with pathology confirmation including immunohistochemistry and flow cytometry to identify the specific subtype. Staging involves PET/CT imaging and often bone marrow biopsy. These records — the pathology report, the staging scans, the treatment records — are the medical foundation of any claim, regardless of which legal theory is pursued.
The proof problem the defense exploits on causation. Non-Hodgkin lymphoma has multiple known risk factors and no single signature cause the way mesothelioma is essentially signature for asbestos. The defense argues that your NHL was idiopathic — arising spontaneously, from unknown causes — and that you cannot prove glyphosate caused it rather than something else. The counter requires two layers of expert proof: general causation (glyphosate can cause NHL in humans, supported by epidemiological studies, the IARC classification, and toxicological mechanism evidence) and specific causation (your glyphosate exposure was sufficient to cause your NHL, supported by dose reconstruction from your usage history, duration and frequency of exposure, and a differential diagnosis that rules out other known causes). This proof architecture is the same regardless of whether your claim is failure-to-warn, design defect, or negligence — the causation proof does not change, only the legal theory through which the company’s conduct is challenged changes.
For families who have lost a loved one to NHL, California allows both survival actions (the estate’s claim for the decedent’s pre-death damages — medical expenses, pain and suffering, lost earnings) and wrongful death claims (the heirs’ claim for loss of financial support, companionship, and consortium). The ruling does not eliminate these claims — it only changes the liability theory through which they must be pursued.
Evidence That Is Dying Right Now: What Exists, Who Holds It, and How Fast It Disappears
The Supreme Court ruling makes evidence preservation more important, not less. When failure-to-warn was the dominant theory, many cases could proceed on relatively broad exposure allegations. Now, with surviving theories requiring more individualized factual development, the specific evidence of your exposure, your diagnosis, and the company’s independent conduct becomes the load-bearing structure of your case.
Your medical records. Complete medical records including pathology reports confirming NHL diagnosis, treatment history, and your treating oncologist’s records. These establish your injury, your diagnosis date, your treatment course, and your damages baseline. Medical records are generally retrievable from providers, but the availability of treating physicians for testimony degrades over time. Your oncologist who treated you in 2019 may have retired, relocated, or passed away by the time your case reaches trial. Obtain the full chart now.
Roundup purchase and usage documentation. Receipts, product containers, employment records for occupational exposure. This is the foundation of specific causation in a post-failure-to-warn landscape. Receipts and product packaging degrade or are discarded — most people do not keep a twenty-year history of weed-killer purchases. Employment records for landscapers, agricultural workers, and municipal employees may be subject to retention schedules and personnel turnover. If you were a municipal employee in Pasadena before the city stopped using Roundup in 2018, or a county worker involved in sediment removal at Devil’s Gate Dam, your employment records and the city’s or county’s pesticide application records are evidence that must be requested before retention schedules allow their destruction.
Internal corporate documents. Internal Monsanto and Bayer corporate documents regarding glyphosate safety research, ghostwriting of scientific papers, and internal knowledge of carcinogenicity risk have already been produced in discovery in prior settled cases. These documents support non-preempted theories including negligence, design defect, and punitive damages by demonstrating corporate knowledge independent of the labeling process. Their availability depends on prior protective orders and confidentiality agreements that may restrict access — but the fact that they exist and have been produced before means they can be obtained again with the right legal process.
EPA regulatory records. EPA regulatory correspondence, registration reviews, and label approval history for Roundup products define the scope of federal labeling approval and help identify the boundary between preempted and non-preempted claims. Federal regulatory records are generally preserved, but Freedom of Information Act requests may be necessary and require processing time.
Witness statements. Co-workers, family members, and supervisors who can corroborate your Roundup exposure. Witness memory degrades, witnesses relocate, and the passage of years turns a clear memory of “he sprayed Roundup every Saturday morning for fifteen years” into a vague “I think he used some kind of weed killer.” Statements should be memorialized promptly.
Expert causation reports. Board-certified oncologists for specific causation, PhD toxicologists for dose-response analysis, and epidemiologists to address the IARC/EPA scientific conflict. Expert retention should occur early to allow adequate case-specific analysis. California’s expert-admissibility standard requires careful preparation, and the defense will challenge causation experts aggressively — especially given the contested scientific landscape between the IARC and EPA positions.
What Your Case May Be Worth After the Ruling
Before the ruling, individual Roundup cancer claims carried values ranging from approximately $75,000 on the low end to $5,000,000 or more on the high end, depending on exposure strength, diagnosis clarity, and the jurisdiction. Bayer’s aggregate resolution exceeding $10 billion across tens of thousands of claims indicates the historical per-claim settlement value was substantial.
The ruling changes this landscape. Cases that were primarily reliant on the failure-to-warn theory — the broad theory that the label should have warned about cancer — face significant value depreciation. The defense will cite the ruling to depress settlement values and to move for dismissal of claims that are pleaded solely as failure-to-warn.
But cases with strong exposure evidence, a clear NHL diagnosis, and compelling corporate misconduct evidence independent of labeling decisions can retain substantial value under surviving theories. Here is what drives post-ruling case value:
Exposure strength. Occupational exposure — a landscaper who mixed and sprayed Roundup daily for years, an agricultural worker who applied it across fields, a municipal employee who sprayed it on city property — is the strongest exposure profile. Repeated residential exposure over many years is next. Marginal or incidental exposure is weakest. The ruling makes exposure documentation more important because specific causation proof is the foundation of every surviving theory.
Diagnosis clarity. A confirmed NHL diagnosis with pathology reports, clear treatment history, and a treating oncologist who can testify is essential. The clearer the diagnosis and the stronger the treatment record, the more compelling the damages.
Corporate misconduct evidence. Internal documents showing the company knew about cancer risk and acted to suppress or minimize that knowledge — independent of the labeling process — support negligence, design defect, and punitive damages theories. This evidence has already been produced in prior cases. The more of it that can be deployed through non-preempted theories, the stronger the case.
California’s damage framework. California applies a pure comparative negligence standard, meaning your own share of fault reduces your recovery but never bars it entirely. California has no statutory cap on non-economic damages in toxic tort cases, meaning pain and suffering, emotional distress, and loss of quality of life are recoverable without an artificial ceiling. Punitive damages remain available where you can demonstrate by clear and convincing evidence that the manufacturer acted with malice, oppression, or fraud — and corporate conduct independent of labeling decisions is the foundation of that showing.
California also allows recovery of economic damages including past and future medical expenses, lost wages, diminished earning capacity, and out-of-pocket costs. For a cancer patient, the medical expense stream alone — chemotherapy, radiation, imaging, follow-up, potential transplant, ongoing monitoring — can run into the hundreds of thousands to over a million dollars.
Past results depend on the facts of each case and do not guarantee future outcomes. What we can tell you honestly is that the ruling eliminates the easiest path to recovery and makes the specific facts of your exposure, your diagnosis, and the company’s independent conduct the decisive factors in what your case is worth.
The Defense Playbook After the Ruling: What Bayer Will Try and How to Counter Each Move
The ruling is the defense’s new favorite weapon. Here is what they will do with it, and what the counter to each move looks like.
Play 1: “Your entire case is preempted.” The defense will file motions to dismiss or for summary judgment arguing that the Supreme Court’s ruling preempts all state-law claims related to Roundup and cancer. The ruling only addressed failure-to-warn claims based on label content — it did not address design defect, negligence in testing, or concealment theories. The counter is to plead the surviving theories with specificity, tying each claim to conduct independent of the label. A properly pleaded design defect claim is not a labeling claim. A properly pleaded negligence claim is about the company’s testing and research conduct, not its label.
Play 2: “The EPA says glyphosate is safe.” The defense will lean on the EPA’s determination that glyphosate is “not likely” carcinogenic. The counter is that the EPA’s position is contested — the IARC, a World Health Organization body, reached the opposite conclusion, and California itself lists glyphosate as a carcinogen under Proposition 65. The scientific disagreement is real, and a jury can hear it. The EPA’s risk assessment and the IARC’s hazard assessment evaluate different questions through different processes. California’s own regulatory determination that glyphosate is a carcinogen is a powerful counterweight in a California courtroom.
Play 3: “Settle cheap or risk losing everything.” The defense will use the ruling to depress settlement values, offering fractions of pre-ruling amounts and telling plaintiffs’ attorneys that the alternative is dismissal. The counter is that surviving theories still support substantial recovery, that California has no non-economic damage cap in toxic tort cases, that punitive damages remain available based on corporate conduct, and that the $10 billion Bayer has already paid demonstrates the company’s own assessment of its exposure. The ruling changed the leverage — it did not eliminate it.
Play 4: “Your exposure was minimal.” The defense will minimize your exposure history, arguing that casual residential use is insufficient to cause cancer. The counter is dose reconstruction by a qualified toxicologist, supported by your documented usage history — purchase receipts, employment records, witness testimony about frequency and duration of use. The stronger your exposure documentation, the weaker this defense.
Play 5: “Your cancer came from something else.” The defense will argue alternative causation — that your NHL was idiopathic, or caused by other risk factors, or that you cannot prove glyphosate rather than something else caused it. The counter is a differential diagnosis by a board-certified oncologist who reviews your exposure history, rules out other known causes, and concludes that glyphosate exposure was a substantial contributing factor to your NHL. This is the same proof that supported failure-to-warn cases — the causation evidence does not change, only the legal theory changes.
Play 6: “Your case is time-barred.” The defense will argue the statute of limitations has expired. For latent diseases like cancer, California applies the discovery rule — the clock starts when you knew or should have known of your injury and its cause. If you were diagnosed with NHL years ago but only recently connected it to Roundup exposure, the clock may have started recently. The defense will argue you should have known earlier. The counter requires careful analysis of when the connection between your diagnosis and glyphosate exposure was reasonably discoverable.
How a Roundup Case Is Actually Built: The Proof Story
Here is how a Roundup cancer case is built under the surviving theories, from the day you call to the day a number is on the table.
Week one: the preservation letter goes out. The day you call, letters go to every entity that holds evidence — Bayer/Monsanto (demanding preservation of internal corporate documents related to glyphosate safety research, internal communications about cancer risk, and post-EPA-approval acknowledgments of carcinogenicity), the EPA (for regulatory correspondence and label approval history), and any employer or municipality whose records document your exposure. The letter is not a formality. It is the legal instrument that converts “we deleted those records” from routine housekeeping into sanctionable spoliation.
Weeks two through four: the medical file is assembled. Your complete medical records are obtained from every treating provider — the oncologist, the radiologist, the pathologist, the surgeon if you had a biopsy, the infusion center, the hospital. The pathology report is the cornerstone: it proves the diagnosis, identifies the subtype, and dates the disease. The treatment records establish the damages: every chemotherapy session, every imaging scan, every hospitalization, every side effect documented in the nursing notes.
Months one through three: the exposure reconstruction. This is the work that the ruling makes more important. Your attorney and a retained toxicologist build your exposure history from every available source: purchase receipts, product containers you still have, credit card records, home improvement store loyalty program data, employment records if exposure was occupational, pesticide application logs if exposure was municipal or commercial, witness statements from co-workers and family members. The goal is a dose reconstruction — an expert opinion, grounded in your specific usage history, about how much glyphosate you were exposed to, over how many years, and at what frequency. This is the foundation of specific causation.
Months three through six: expert retention and report preparation. A board-certified oncologist prepares a specific causation opinion linking your glyphosate exposure to your NHL. A PhD toxicologist prepares a dose-response analysis. An epidemiologist prepares a report addressing the IARC/EPA scientific conflict and the body of literature supporting the glyphosate-NHL association. Each expert must survive a Daubert challenge — the defense will attack their methodology, their reliance on the IARC classification, and their ability to attribute your specific cancer to glyphosate. California’s expert-admissibility standard requires careful preparation.
Months six through twelve: discovery. Written discovery goes to Bayer/Monsanto seeking the internal corporate documents that support negligence, design defect, and concealment theories — the safety studies, the internal communications, the ghostwriting allegations, the post-EPA-approval internal acknowledgments of cancer risk. Depositions follow, where corporate representatives explain under oath what the company knew, when it knew it, and what it did about it. The discovery target is not the label — it is the conduct independent of the label.
The number at the end. The settlement value or trial verdict is built from all of it: the strength of your exposure evidence, the clarity of your diagnosis, the weight of the corporate misconduct evidence, the credibility of your experts, and the skill with which your attorney weaves these into the surviving legal theories. The ruling eliminated the shortcut. It did not eliminate the destination.
Local Exposure: Pasadena, LA County, and Caltech
The article documents a specific local history of Roundup use in the Pasadena area that is directly relevant to California residents evaluating potential exposure claims.
The City of Pasadena stopped using Roundup on city property in 2018. If you were a Pasadena municipal employee — a parks worker, a maintenance employee, a groundskeeper — who handled or applied Roundup on city property before that date, your employment records and the city’s pesticide application records are evidence of occupational exposure. Claims against the City of Pasadena would be governed by the California Tort Claims Act, which requires filing a government claim within six months of the date you discovered (or should have discovered) your injury and its cause. That is a dramatically shorter deadline than the general personal injury statute of limitations, and it is a deadline that can quietly expire while you are still in treatment.
The Los Angeles County Board of Supervisors banned Roundup use in 2019 after it was discovered the herbicide had been sprayed near a heliport in unincorporated Pasadena. The unincorporated Pasadena area falls under Los Angeles County jurisdiction, not Pasadena municipal governance — meaning any county-level exposure claims would be filed in LA County Superior Court and would also be subject to the California Tort Claims Act’s government claim deadlines if the county is a defendant. LA County’s own pesticide application records for the period before the 2019 ban are discoverable evidence.
Roundup was also used during sediment removal work at Devil’s Gate Dam, which spans the Arroyo Seco canyon between Pasadena and La Cañada Flintridge. The dam has been the subject of extensive environmental remediation efforts following post-station-fire sediment accumulation. Workers involved in that sediment removal who were exposed to Roundup during the project may have occupational exposure claims. If those workers were employed by LA County Public Works, government tort claims deadlines apply. If they were employed by a private contractor, a third-party tort claim against the contractor — and potentially against Monsanto/Bayer on product liability theories — may be available without the government claim deadline.
In 2019, Caltech prohibited the use of glyphosate-based herbicides at its student housing facilities after a landscaper applied a generic version of the chemical in playground and courtyard areas. If you were a Caltech student, a resident of Caltech housing, or a child who played in those courtyard areas, you may have been exposed to glyphosate through a generic product rather than branded Roundup. Generic glyphosate manufacturers face the same FIFRA preemption analysis for failure-to-warn claims, but design defect and negligence theories may apply. The specific product used, the manufacturer of that generic product, and the timeline of application are all facts that must be developed from Caltech’s facilities records and the landscaper’s documentation.
Your First Steps: The Evidence Clock Is Running
The Supreme Court ruling makes the early weeks after you decide to act more important, not less. Here is what to do — and what not to do — in the days ahead.
Document your exposure history in writing. Write down everything you can remember about your Roundup use: when you started, when you stopped, how often you used it, how much you used, where you bought it, what size containers you purchased, whether you mixed it or used a pre-mixed spray, whether you wore protective equipment, whether you sprayed it at home, at work, or both. If your exposure was occupational, document your job title, your employer, the years you worked, the frequency of application, and whether co-workers can corroborate. This written history is the starting point for your attorney’s exposure reconstruction.
Gather physical evidence. If you still have Roundup containers, product packaging, or purchase receipts, save them. Do not discard anything. If you have employment records, time cards, or pay stubs from a job where Roundup exposure occurred, gather them. If you have photographs of yourself applying Roundup or working in areas where it was sprayed, find them. Physical evidence corrodes, gets thrown out in garage cleanouts, and disappears in moves — secure it now.
Obtain your complete medical records. Contact every treating provider — your oncologist, your primary care physician, the hospital where you were diagnosed, the infusion center where you received chemotherapy — and request your complete records, including pathology reports, imaging studies, treatment notes, and medication records. You are entitled to your own medical records. Do not wait for an attorney to request them; you can start the process yourself today.
Identify witnesses. Make a list of everyone who can corroborate your exposure — family members who saw you use Roundup, co-workers who worked alongside you, supervisors who directed you to use it, neighbors who watched you spray your yard. Their memories are fading. Their contact information changes. Write down their names and phone numbers now.
Do not sign anything from Bayer, Monsanto, or their representatives. If you receive any communication from the company, its insurers, its claims administrators, or anyone representing the company’s interests — do not sign it, do not return it, do not respond to it without speaking to an attorney first. A release printed on the back of a settlement check is the oldest trick in the insurance playbook. A quick payment that arrives before you understand your full range of legal options is not generosity — it is strategy.
Do not give a recorded statement. If anyone representing the company or its insurers asks you to describe your Roundup use or your medical history “just for our records” — on a recording, in writing, or in any format — decline. A recorded statement is engineered to be quoted against you. Everything you say can and will be parsed for inconsistencies, gaps, and admissions that serve the defense.
Call a toxic tort attorney. Not a generalist. Not a firm that handles “personal injury” broadly. A toxic tort attorney who understands FIFRA preemption, who knows which theories survive the ruling, who has experience with mass tort litigation, and who can evaluate your specific exposure history and diagnosis against the surviving legal landscape. The consultation should be free. The evaluation should be specific to your facts. And the attorney should be honest with you about what the ruling changed and what it did not.
The Statute of Limitations: How Long You Have
California’s statute of limitations for personal injury claims is two years from the date the cause of action accrues, under Code of Civil Procedure § 335.1. For wrongful death claims, the deadline is also two years from the date of death.
For toxic tort cases involving latent disease — cancer that may not appear until years or decades after exposure — California applies the discovery rule. Under the discovery rule, the cause of action does not accrue, and the statute of limitations does not begin to run, until the plaintiff discovers or through reasonable diligence should have discovered both the injury and its causal connection to the wrongful conduct. This means: if you were diagnosed with non-Hodgkin lymphoma years ago but only recently learned that your Roundup exposure may have caused it, the clock may have started when you made that connection — not when you were diagnosed.
This is not a blank check. The defense will argue that you “should have known” earlier — that the connection between Roundup and cancer has been publicly discussed for years, and that a reasonably diligent person would have investigated the cause of their cancer sooner. The date the clock started is a contested factual question that can determine whether your case is alive or dead.
There is also an outer boundary to be aware of. Some jurisdictions apply a statute of repose — an absolute deadline that can cut off a claim even before discovery. Whether California’s framework includes a repose period that applies to your specific situation is a question that must be evaluated by an attorney familiar with the current state of California toxic tort law.
If your exposure was through a government employer — the City of Pasadena, LA County, or another public entity — the California Tort Claims Act imposes a separate, much shorter deadline. You must file a formal claim with the government entity within six months of the date you discovered (or should have discovered) your injury and its cause. Missing this deadline can permanently bar a claim against the government entity, even if the two-year statute of limitations has not yet expired. This six-month window is the single most dangerous deadline in a municipal-exposure Roundup case, and it is one that many people never hear about until it has already passed.
The safest approach is to treat every deadline as if it is running now and to have an attorney confirm the specific deadlines that apply to your case. Waiting to “see how the law develops” after the Supreme Court ruling is not a strategy — it is a way to let the clock run out.
Frequently Asked Questions
Can I still file a Roundup cancer lawsuit after the Supreme Court ruling?
Yes, in many cases you can still file. The ruling specifically preempts state-law failure-to-warn claims that seek to require cancer warnings on EPA-approved Roundup labels. It does not eliminate all claims against the manufacturer. Design defect claims, negligence in safety testing claims, and negligent concealment claims — theories that are not premised on the content of the label — may still be viable under California law. Whether your specific case can be filed depends on the strength of your exposure evidence, your diagnosis, the surviving legal theories that fit your facts, and whether the statute of limitations has expired. A toxic tort attorney can evaluate these factors in a free consultation.
Is my existing Roundup case over because of the ruling?
If your case was filed and is pending, it is not automatically over. The ruling gives the defense a powerful argument to dismiss failure-to-warn claims, and your attorney will need to evaluate whether your case can proceed on alternative theories. If your case was pleaded solely as a failure-to-warn claim, it faces a serious preemption challenge. If your case includes design defect, negligence, or concealment theories, those claims may survive. Contact your current attorney immediately to discuss how the ruling affects your specific case and whether amended pleading is necessary to pursue surviving theories.
What if I was exposed to Roundup at work in Pasadena or LA County?
Occupational exposure is among the strongest exposure profiles for a Roundup cancer claim. If you were a municipal employee in Pasadena before the city stopped using Roundup in 2018, or a county worker in areas where LA County sprayed it before the 2019 ban, or a worker involved in sediment removal at Devil’s Gate Dam where Roundup was used, your employment records and the government’s pesticide application records are evidence of your exposure. If your employer was a government entity, you must file a claim under the California Tort Claims Act within six months of discovering your injury and its cause — a deadline that is much shorter than the general two-year statute of limitations. Do not wait to have this deadline evaluated.
What if I was exposed to a generic glyphosate product, not branded Roundup?
The article references a generic glyphosate product applied at Caltech facilities. Generic glyphosate manufacturers would likely face the same FIFRA preemption analysis for failure-to-warn claims as Monsanto does — if their labels were EPA-approved, failure-to-warn claims seeking additional cancer warnings would likely be preempted. However, design defect and negligence theories may still apply to generic manufacturers. The specific product used, the manufacturer, and the timeline of application must be identified from facilities records. If you were exposed to a generic product, your attorney needs to identify the manufacturer and evaluate claims against that specific entity.
How much is my Roundup cancer case worth after the ruling?
Case values range widely depending on the strength of your exposure evidence, the clarity of your NHL diagnosis, the corporate misconduct evidence that can be deployed through surviving theories, and the specific damages you have suffered. Pre-ruling values ranged from approximately $75,000 on the low end to $5,000,000 or more on the high end. The ruling will likely depress values for cases that relied primarily on failure-to-warn, while cases with strong occupational exposure, clear diagnosis, and compelling corporate misconduct evidence may retain substantial value under design defect, negligence, and concealment theories. California has no statutory cap on non-economic damages in toxic tort cases, meaning pain and suffering, emotional distress, and loss of quality of life are fully recoverable. Punitive damages remain available where corporate conduct independent of labeling decisions demonstrates malice, oppression, or fraud. Past results depend on the facts of each case and do not guarantee future outcomes.
How long do I have to file a Roundup cancer lawsuit in California?
California’s personal injury statute of limitations is two years from the date the cause of action accrues, under Code of Civil Procedure § 335.1. For latent diseases like cancer, the discovery rule applies — the clock starts when you knew or should have known of your injury and its causal connection to Roundup exposure. For wrongful death claims, the deadline is two years from the date of death. If your exposure was through a government employer, the California Tort Claims Act requires filing a claim with the entity within six months, which is a dramatically shorter deadline. The specific deadlines that apply to your case depend on when you were diagnosed, when you connected your diagnosis to Roundup exposure, and whether any government entity is involved. An attorney can confirm your deadlines in a free consultation.
What is the difference between failure-to-warn and design defect in a Roundup case?
Failure-to-warn claims argue that the product’s label should have included a cancer warning and did not — the claim is about the adequacy of the warning on the label. Design defect claims argue that the product itself was unreasonably dangerous in its formulation, regardless of what the label said — the claim is about the product’s design, not its labeling. The Supreme Court’s ruling preempts failure-to-warn claims because they seek to impose a labeling requirement that conflicts with the EPA’s approved label. Design defect claims are not directly addressed by the ruling because they do not seek to change the label — they challenge the product’s design. This distinction is the key to understanding which claims survive.
What should I do right now to protect my Roundup case?
Four things, immediately. First, write down your complete Roundup exposure history — when, where, how often, how much, for how many years. Second, gather any physical evidence you still have — product containers, receipts, employment records, photographs. Third, obtain your complete medical records including pathology reports confirming your NHL diagnosis. Fourth, call a toxic tort attorney for a free case evaluation. Do not sign anything from the company or its representatives, do not give a recorded statement, and do not wait to “see how the law develops” — the statute of limitations is running, and the evidence is degrading.
Does the Supreme Court ruling affect cases where the plaintiff has already died?
The ruling affects the liability theory, not the plaintiff’s status. If a Roundup cancer plaintiff has died, their estate may pursue a survival action for pre-death damages (medical expenses, pain and suffering, lost earnings) and their heirs may pursue a wrongful death claim for loss of financial support, companionship, and consortium. Both claims must now be pursued through surviving legal theories — design defect, negligence, concealment — rather than failure-to-warn. The wrongful death statute of limitations in California is two years from the date of death, and the discovery rule may apply to the causal connection between the death and Roundup exposure. If the exposure was through a government employer, the six-month government claim deadline may apply.
Can I still get punitive damages in a Roundup case after the ruling?
Punitive damages remain available in California where you can demonstrate by clear and convincing evidence that the manufacturer acted with malice, oppression, or fraud. The ruling weakens the punitive framework to the extent that many punitive theories were built on the failure-to-warn conduct — the argument that the company knew about cancer risk and failed to warn. But punitive damages can also be pursued based on corporate conduct independent of labeling decisions: suppression of safety research, misrepresentation of scientific data to regulators and the public, ghostwriting of scientific papers, and internal acknowledgments of cancer risk that were not reflected in the company’s public statements or regulatory submissions. The internal corporate documents that support these non-labeling theories of punitive conduct are the same documents that support negligence and concealment claims. The ruling narrows the path to punitive damages — it does not close it.
Why This Firm
We are Attorney911 — The Manginello Law Firm, PLLC. We are a trial firm that takes California toxic tort and catastrophic injury cases, working with local counsel and pro hac vice admission where required. We do not maintain a California office, and we will tell you honestly if your case requires direct local counsel that we are not positioned to provide. What we bring is the depth of a firm that has spent over two decades fighting for injured people against corporations and insurance companies.
Ralph Manginello is our Managing Partner — a trial attorney with 27+ years of practice, admitted in Texas in 1998 and admitted to the U.S. District Court for the Southern District of Texas. He was a journalist before he was a lawyer, which means he reads documents the way a reporter reads documents — looking for the sentence the company did not want to write. He has spent his career in courtrooms, including federal court, trying cases against companies that hurt people and then tried to pay them less than the harm was worth. He is a member of the Texas Trial Lawyers Association and the Houston Bar Association, and he leads the active $10M+ hazing lawsuit against Pi Kappa Phi at the University of Houston — a case that is live, not a marketing claim.
Lupe Peña is our associate attorney — a former insurance-defense attorney who spent years inside a national defense firm, in the rooms where adjusters and their software decided how to deny, delay, and devalue claims. He sat on the other side of the table. He knows how claims are valued from the inside — how reserves are set in the first 48 hours, how recorded statements are engineered, how settlement offers are calibrated to extract a release before the full medical picture is known. Now he uses that knowledge for injured clients. He is fluent in Spanish and conducts full client consultations in Spanish without an interpreter — hablamos Español — because the family that prays in Spanish deserves the same depth of representation as any other family.
Our fee is contingency: 33.33% before trial, 40% if the case goes to trial. We don’t get paid unless we win your case. The consultation is free. The call is confidential. And we have 24/7 live staff — not an answering service, but people who can take your call at any hour and start the process of protecting your evidence and your rights.
We have recovered more than $50 million for our clients across our years of practice. Past results depend on the facts of each case and do not guarantee future outcomes. What we can guarantee is that when you call, you will speak to a firm that understands the Supreme Court ruling, that knows which theories survive it, and that will give you an honest evaluation of your specific case — not a sales pitch built on a headline.
The Supreme Court ruling changed the Roundup litigation landscape. It did not end it. What it did was make the specific legal theory your attorney chooses, the strength of your individual exposure evidence, and the depth of your attorney’s understanding of the surviving claims more important than they have ever been.
The evidence is degrading. The statute of limitations is running. The company is counting on the headline to make you give up before you call.
Call us at 1-888-ATTY-911 (1-888-288-9911). The consultation is free. The call is confidential. And the conversation will be the first step in understanding what your case is actually worth — not what the headline says it is worth, but what your specific facts, your specific diagnosis, and the surviving legal theories can support. Hablamos Español.